Skip to main content
Figure 1 | BMC Medicine

Figure 1

From: A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model

Figure 1

Differences in disease onset, survival, and clinical score between the acute minor histocompatibility antigen (miHAg) mismatched and the hyperacute major histocompatibility complex (MHC) fully mismatched graft-versus-host disease (GVHD) models. Myeloablatively conditioned recipients were transplanted as described or left untreated and monitored for weight change, clinical GVHD symptoms, and survival daily after hematopoietic cell transplantation (HCT). (A) Weight change is displayed relative to day 0 of HCT. Graphs show summarized data from two independent experiments for MHC major mismatched BALB/c mice (, left panel) and miHAg mismatch BALB/b recipients (■, right panel) separately. In both panels a syngeneic control () and a bone marrow control () were added. Error bars display means plus or minus SEM. (B) Clinical GVHD scoring rapidly increased in symptoms in the MHC major mismatch model (, left panel). In the miHAg mismatch group (, right panel) symptoms continuously increased compared to syngeneic controls (). (C) MHC major mismatch recipients (, left panel) developed hyperacute GVHD and most animals died within 14 days after HCT. In contrast, BALB/b recipients (miHAg mismatch, ■, right panel) mostly survived until day +30. Mice that received lethal irradiation without subsequent HCT died from the consequences of myeloablation (×). In both panels a syngeneic control () and a bone marrow control () were added. Graphs show summarized data from two independent experiments for MHC major mismatch recipients (, left panel) and miHAg mismatch recipients (■, right panel) separately.

Back to article page